Expert Interview
A look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Ticker(s): SNDX, KURAInstitution: Detroit Medical Center
- Board Certified Hematologist and oncologist
- Currently manages 120 CLL patients and 30 SLL patients
- Has prescribed Imbruvica to as a first line treatment to ~40 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
